Abstract:Cancer cells evolve to be refractory to the intrinsic programmed cell death mechanisms, which ensure cellular tissue homeostasis in physiological conditions. Chemotherapy using cytotoxic drugs seeks to eliminate cancer cells but spare non-cancerous host cells by exploring a likely subtle difference between malignant and benign cells. Presumably, chemotherapy agents achieve efficacy by triggering programmed cell death machineries in cancer cells. Currently, many major solid tumors are treated with chemotherapy composed of a combination of platinum agents and taxanes. Platinum agents, largely cis-platin, carboplatin, and oxaliplatin, are DNA damaging agents that covalently form DNA addicts, triggering DNA repair response pathways. Taxanes, including paclitaxel, docetaxel, and cabazitaxel, are microtubule stabilizing drugs which are often very effective in purging cancer cells in clinical settings. Generally, it is thought that the stabilization of microtubules by taxanes leads to mitotic arrest, mitotic catastrophe, and the triggering of apoptotic programmed cell death. However, the precise mechanism(s) of how mitotic arrest and catastrophe activate the caspase pathway has not been established. Here, we briefly review literature on the involvement of potential cell death mechanisms in cancer therapy. These include the classical caspase-mediated apoptotic programmed cell death, necroptosis mediated by MLKL, and pore forming mechanisms in immune cells, etc. In particular, we discuss a newly recognized mechanism of cell death in taxane-treatment of cancer cells that involves micronucleation and the irreversible rupture of the nuclear membrane. Since cancer cells are commonly retarded in responding to programmed cell death signaling, stabilized microtubule bundle-induced micronucleation and nuclear membrane rupture, rather than triggering apoptosis, may be a key mechanism accounting for the success of taxanes as anti-cancer agents.

Live Morphological Analysis of Taxol-Induced Cytoplasmic Vacuolization [corrected] in Human Lung Adenocarcinoma Cells.

Live morphological analysis of taxol-induced cytoplasmic vacuoliazation in human lung adenocarcinoma cells

Taxol Induces Caspase-Independent Cytoplasmic Vacuolization and Cell Death Through Endoplasmic Reticulum (ER) Swelling in ASTC-a-1 Cells.

Fluorescence Imaging Analysis of Taxol-Induced Astc-A-1 Cell Death with Cell Swelling and Cytoplasmic Vacuolization

TAXOL INDUCES CELL DEATH WITH CYTOPLASM VACUOLIZATION IN PARAPTOSIS-LIKE BUT NOT ONCOSIS FASHION IN ASTC-a-1 CELLS

Taxol Induces Concentration-Dependent Apoptotic and Paraptosis-Like Cell Death in Human Lung Adenocarcinoma (Astc-a-1) Cells

Fluorescence Analysis of Taxol-Induced Paraptosis-Like Independent of Caspase-3 Activation

Study on Taxol in Inhibiting Human Leukemia Cell Proliferation and Inducing Apoptosis

Taxol induces caspase-independent cytoplasmic vacuolization and cell death

Intratumoral Injection of Taxol in Vivo Suppresses A549 Tumor Showing Cytoplasmic Vacuolization.

Taxol Induces Paraptosis Independent of Both Protein Synthesis and MAPK Pathway.

Taxol induces concentration-dependent phosphatidylserine (PS) externalization and cell cycle arrest in ASTC-a-1 cells

Taxol-Induced Paraptosis-Like A549 Cell Death is Not Senescence

Mechanism of Taxol-Induced Apoptosis in Human Breast Cancer Cells

Reactive oxygen species (ROS) is not a promotor of taxol-induced cytoplasmic vacuolization

Taxol toxicity. Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest

Involvement of Mitochondrial Permeability Transition Pore Opening in 7-Xylosyl-10-deacetylpaclitaxel-induced Apoptosis.

AdIκBα transfer reverses the chemoresistance to taxol by inducing apoptosis in nude mice with human non-small cell lung cancer

Excipient of paclitaxel induces metabolic dysregulation and unfolded protein response

Taxol-induced apoptotic cell death in suspension cultures of Taxus cuspidata

Cell death in cancer chemotherapy using taxanes